Rock Springs Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Rock Springs Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-289,754	Closed	-$1.3M	–	140
2022 Q1	$1.3M	Hold	289,754	–	–	0.03%	133
2021 Q4	$1.97M	Hold	289,754	–	–	0.05%	128
2021 Q3	$2.11M	Hold	289,754	–	–	0.04%	140
2021 Q2	$2.9M	Hold	289,754	–	–	0.06%	141
2021 Q1	$2.77M	Hold	289,754	–	–	0.06%	137
2020 Q4	$3.18M	Sell	289,754 -77,745	-21%	-$820K	0.07%	142
2020 Q3	$3.26M	Buy	+367,499	New	+$4.18M	0.08%	135

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rock Springs Capital Management's PSTX Position: Q2 2022 in Review

Rock Springs Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2022, closing a stake of 289,754 shares — an estimated $1.3M sold.

Rock Springs Capital Management first reported a position in PSTX in Q3 2020 and held it in 7 quarters. The position peaked at $3.26M in Q3 2020. 56 funds tracked by Wall St. Rank hold PSTX as of Q2 2022.

Rock Springs Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Rock Springs Capital Management sold 289,754 Poseida Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.3M.
Rock Springs Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Rock Springs Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $3.26M in Q3 2020.
56 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Rock Springs Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.